Investing.com - Vyne Therapeutics (NASDAQ: VYNE) reported first quarter EPS of $-1.740, $1.59 worse than the analyst estimate of $-0.150. Revenue for the quarter came in at $100K versus the consensus estimate of $300K.
Vyne Therapeutics's stock price closed at $6.100. It is up 51.630% in the last 3 months and down -8.700% in the last 12 months.
Vyne Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Vyne Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Vyne Therapeutics's Financial Health score is "fair performance".
Check out Vyne Therapeutics's recent earnings performance, and Vyne Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar